DEF: Supernus 2026 Annual Meeting Proxy Statement

Supernus Pharmaceuticals schedules its 2026 Annual Meeting of Stockholders for June 18, 2026, to address director elections, executive compensation, and equity plan expansion.

Summary

• The 2026 Annual Meeting of Stockholders will be held virtually on June 18, 2026, at 10:00 A.M. EDT.
• Stockholders will vote on the election of two Class II directors: Frederick M. Hudson and Charles W. Newhall, III.
• The meeting includes a non-binding advisory vote on executive compensation (Say-on-Pay).
• Stockholders will vote to ratify the appointment of KPMG LLP as the independent registered public accounting firm for 2026.
• A proposal is included to amend the 2021 Equity Incentive Plan to increase the number of shares available for issuance by 4,000,000.
• As of April 29, 2026, there were 58,039,721 shares of common stock outstanding.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine governance filing. While the company faces market headwinds reflected in negative TSR, the proposals are standard administrative actions for a public company.

Positives

• Over 96% of votes cast at the 2025 Annual Meeting approved the executive compensation program.
• The company maintains a strong pay-for-performance alignment, with a significant portion of executive compensation tied to corporate objectives and stock price appreciation.
• The Board of Directors has successfully separated the roles of CEO and Chairman since 2005.
• The company has a robust Incentive Compensation Recoupment Policy (clawback) in place.

Negatives

• The company recorded a net loss in 2025, impacted by $89.5 million in amortization expenses for intangible assets.
• The company's total shareholder return (TSR) for 2025 was negative 38.6%.
• The Governance and Nominating Committee did not hold a meeting during the 2025 fiscal year.

Risks

• Failure to approve the increase in shares for the 2021 Equity Incentive Plan could hinder the company's ability to attract and retain critical talent.
• Cybersecurity threats remain a significant risk, with the Audit Committee specifically tasked with oversight of IT-related risks.
• The company faces potential risks associated with the development and commercialization of its CNS disease product pipeline.

Future Outlook

The company intends to continue its strategic focus on developing and commercializing products for the treatment of central nervous system (CNS) diseases, supported by selective investments in its R&D pipeline and potential corporate acquisitions.

Management Comments

• The Board of Directors believes the proposed increase in shares for the 2021 Equity Incentive Plan is essential to continue attracting and retaining highly qualified personnel.
• The Board emphasizes that the current leadership structure, with separate CEO and Chairman roles, has worked effectively for the company.

Industry Context

StockSavvy.ai notes that Supernus is operating within a highly competitive biopharmaceutical landscape, where equity-based compensation is a standard tool for talent retention. The company's focus on CNS disorders aligns with broader industry trends toward specialized therapeutic areas.

Comparison to Industry Standards

• The company's peer group includes established biopharmaceutical firms such as Alkermes Plc, Axsome Therapeutics, and PTC Therapeutics.
• The company's compensation practices, including the use of Aon for benchmarking, are consistent with standard practices for companies of similar market capitalization ($800 million to $7.3 billion).
• The 81:1 CEO-to-median-employee pay ratio is within the range observed for mid-cap pharmaceutical companies.

Corporate Governance

Legal Proceedings

• The company is not currently involved in any pending litigation or proceedings requiring indemnification of directors or officers.

Related Party Transactions

• The company employed an adult daughter of CEO Jack Khattar in a non-executive role during 2025; her employment ended in December 2025.

Stakeholder Impact

• Shareholders are asked to vote on director elections and equity plan expansion.
• Employees and executives are impacted by the proposed increase in equity incentive availability.
• The company continues to provide standard benefits to employees and maintains insurance for directors and officers.

Next Steps

• Hold the 2026 Annual Meeting of Stockholders on June 18, 2026.
• Execute the proposed amendment to the 2021 Equity Incentive Plan if approved by stockholders.
• Continue the annual performance management cycle for executive officers.

Key Dates

Keywords

Supernus Pharmaceuticals, Proxy Statement, Annual Meeting, Equity Incentive Plan, Executive Compensation, Corporate Governance, Biotechnology